"Cutaneous
CD30+ (Ki-1) anaplastic large-cell lymphoma (cutaneous CD30+ ALCL) is
clinically and pathologically heterogeneous (varying), leading to some
difficulty in its diagnosis and classification.
Expression of CD30 (an
activation marker for B or T cells) in more than 75% of neoplastic
cells characterizes this group of lymphoproliferative disorders.
Based on clinical manifestations, cutaneous CD30+
ALCL can be subdivided mainly into
1) primary cutaneous (skin) form without extracutaneous involvement at
presentation, or
2) systemic form with secondary skin involvement at
presentation." 1